OH-PROCTER-&-GAMBLE
5.8.2021 20:51:08 CEST | Business Wire | Press release
As an Olympic sponsor for the past 10 years, Procter & Gamble’s (NYSE: PG) focus is on celebrating and supporting the unique journeys athletes take on the road to their Olympic dreams, including the causes they champion and the work they do to drive positive change in their communities. In the lead up to the Olympic Games Tokyo 2020, P&G was inspired by the selfless actions of Olympic and Paralympic athletes around the world who stepped up and served others. This led P&G to create the Athletes for Good Fund in partnership with the International Olympic Committee (IOC) and International Paralympic Committee (IPC). Its purpose is to honor and fuel the work of Olympic and Paralympic athletes and hopefuls who lend their time, talent, and resources to charitable causes in the areas of Community Impact, Equality & Inclusion, and Environmental Sustainability. For Tokyo 2020, Athletes for Good Fund provided more than $500,000 in grants to help fuel the efforts of the recipients’ charities of choice.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005996/en/
Today, during a virtual panel discussion dubbed “Champions and the Causes They Champion,” co-hosts Olympic Gold Medalist Nastia Liukin (USA, Gymnastics Legend) and Olympic Silver Medalist Gus Kenworthy (Great Britain, Freestyle Skiing) were joined by four athletes who are not only incredible competitors, but also display compassion, humanity, and goodness on and off the field of play. Through their inspiring stories, we learned how each panelist found motivation based on their personal experiences, along with their passion to get involved to create positive change within their communities. Panelists included:
- Mariah Duran* , USA, Skateboarding: Having experienced firsthand the intimidation of competing in a male-dominated sport with few female mentors, Mariah serves as a role model, mentor, and advocate for young girls in skate. Through her work with Skate Like A Girl, she encourages the next generation of girls to continue pursuing their passion.
- Alice Dearing* , Great Britain, Swimming: As the first Black woman to swim for Team Great Britain at any Olympic Games, Alice has experienced the barriers within the sport of swimming that are faced among people of color. Taking matters into her own hands, Alice is a lead ambassador for the Black Swimming Association (BSA), focusing on increasing participation and changing attitudes to attract more Black people to understand the importance of learning to swim.
- Brian Afanador* , Puerto Rico, Table Tennis: After Hurricane Maria left a devastating effect on Puerto Rico, Brian used his platform as an Olympic athlete to expand awareness to help his community. In collaboration with #Yonomequito Foundation, he has helped to rebuild homes and provide necessities, like food, fresh water, and emergency services to local families in need.
- Erica Sullivan , USA, Swimming: As an openly gay, Asian American swimmer, Erica has stepped up to advocate for intersectional equality in sport. During Tokyo 2020, she used her press conference as an opportunity to bring awareness to minority groups, including the LGBTQ+ community.
“The spirit of the Olympic Games has the power to lift us up and unite us, and these incredible athletes have all taken that spirit beyond the Olympic and Paralympic Movement, and into their communities with a goal of creating positive change,” said host Nastia Liukin. “It’s inspiring to see organizations, like P&G, continuing to celebrate athletes both on and off the field, supporting their efforts to fuel good in communities so others will be inspired to do the same.”
“For me, being an Olympian is much more than just excelling at my sport; it’s also about using my platform to help the next generation of women skaters coming up reach their potential and dream big,” Mariah Duran shared. “I would not be where I am today without the community and experiences I got at Skate Like A Girl. This organization is a prominent voice for gender equality and inclusion in skateboarding and their events, camps and after school programs help make an unreal scenario, real. I am so appreciative of P&G and Athletes for Good for supporting them.”
You can view the full panel conversation here .
*Athletes for Good Fund Grant recipient
Spotlighting Those Who Lead with Love During Tokyo 2020
Throughout Tokyo 2020, P&G took its commitment to supporting athletes a step further by donating an additional two grants to the chosen charities of athletes who used their Olympic Games platform to serve and support others in Tokyo. Along with Erica Sullivan, P&G extended a donation to Pita Taufatofua (Tonga, Taekwondo), who inspired people everywhere with his generosity towards the athlete community on the ground in Tokyo. The three-time Olympian, who has 15 years of volunteer experience in the youth mental health space, publicly recognized the immense amount of pressure that athletes are put under when competing at an elite level and invited athletes to reach out to him for counseling and advice. His call to action resulted in hundreds of exchanges with athletes, both via social media and in-person at Tokyo 2020. For his efforts to serve as a sounding board for athletes and provide an uplifting voice of support, P&G is proud to recognize that the good that Pita does, is what truly makes him great.
The Athletes for Good Fund and Tokyo 2020 athlete grant donations are helping P&G to achieve its goal of reaching 2,021 Acts of Good in 2021 to support its Lead with Love campaign.
You can learn more about P&G’s Lead with Love commitment here: https://us.pg.com/lead-with-love/ .
About P&G’s 2,021 Acts of Good in 2021
At P&G, supporting our communities, fostering equality and inclusion, and protecting the planet is embedded in how we do business. We believe we have a responsibility to help improve everyday life — through the products we create and the positive impact our brands and Company can have. Under our Lead with Love campaign, P&G and its brands have committed to 2,021 acts of good this year.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005996/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
